VU-29
产品说明书
 |
同义名 : | - |
| CAS号 : | 890764-36-0 | |
| 货号 : | A927285 | |
| 分子式 : | C22H16N4O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 384.39 | |
| MDL号 : | MFCD12546140 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(130.08 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | VU 29 is a potent allosteric potentiator at the rat mGlu5 receptor (EC50 = 9 nM); binds to the MPEP allosteric site (Ki app = 244 nM); Selective for mGlu5 over mGlu1 and mGlu2 receptors (EC50 values are 557 nM and 1.51 μM for mGlu1 and mGlu2 respectively)[1]. VU-29 can inhibit the maintenance of ethanol-induced CPP, and that treatment duration contributes to this effect of VU-29. Furthermore, VU-29 effect was reversed by pretreatment with either MTEP (the mGlu5 receptor antagonist), or MK-801 (the N-methyl-D-aspartate-NMDA receptor antagonist)[2]. VU-29, given before acute ethanol administration, prevented the ethanol-induced impairments in spatial memory retrieval. Furthermore, VU-29 given before the testing session on the first day of abstinence facilitated NOR (novel object recognition) performance in ethanol-withdrawn rats at 4- and 24-h delay after administration. VU-29 normalized ethanol withdrawal induced increase in expression of mGlu5 receptor protein in the hippocampus, prefrontal cortex, and striatum, as well as expression of mGlu2 receptor protein in the hippocampus[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.60mL 0.52mL 0.26mL |
13.01mL 2.60mL 1.30mL |
26.02mL 5.20mL 2.60mL |
| 参考文献 |
|---|